Investor Relations
Nov 09, 2018
OPKO Health Reports Third Quarter 2018 Financial Results MORE >>
Nov 08, 2018
BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services MORE >>
Nov 08, 2018
OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018 MORE >>
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>

Press Releases

All Releases
OPKO Health Provides Update on hGH-CTP Clinical Programs
Dec 30, 2016
Commenced data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults   Initiated Global Pediatric Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Children MIAMI , Dec. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc.
OPKO Health to be Added to the NASDAQ Biotechnology Index
Dec 19, 2016
MIAMI , Dec. 19, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI) effective as of the opening of trading on Monday, December 19, 2016. The NASDAQ Biotechnology Index is designed to track the
OPKO Health to Participate at Three Investment Conferences in December
Nov 30, 2016
MIAMI , Nov. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that its senior management team will host one-on-one investor meetings with institutional investors participating at the following investor conferences in December: Evercore ISI MedTools Investor Conference taking
OPKO Announces U.S. Launch of RAYALDEE™
Nov 23, 2016
MIAMI , Nov. 23, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK), today announced that it will commence shipments of RAYALDEE™ (calcifediol) extended-release capsules to distributors in the United States on Tuesday, November 29, 2016 .  The product will be available nationwide at retail
OPKO Presents Data on RAYALDEE® at ASN Kidney Week 2016
Nov 17, 2016
MIAMI , Nov. 17, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK), announced that data on RAYALDEE (calcifediol) extended-release capsules as a treatment for secondary hyperparathyroidism (SHPT) in stage 3 and 4 chronic kidney disease patients with vitamin D insufficiency will be presented
OPKO Health Reports Third Quarter Financial and Operating Results
Nov 07, 2016
Consolidated revenue increased to $298.0 million for the three months ended September 30, 2016 from $143.0 million for the comparable period of 2015.  Consolidated revenue for the nine months ended September 30, 2016 increased to $946.2 million from $215.5 million for the comparable period of 2015.
OPKO to Announce Third Quarter Operating and Financial Results on November 7, 2016
Nov 03, 2016
MIAMI , Nov. 03, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three months ended September 30, 2016 , after the close of the U.S. financial markets on Monday, November 7, 2016 .  OPKO's senior management will provide a business update
OPKO Health Enters Companion Animal Health Market
Oct 27, 2016
MIAMI , Oct. 27, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today its entry into the animal health market.  The OPKO animal health team will operate as a specialty business unit in cooperation with OPKO Spain, which is already in this business, and OPKO Ireland , which has
OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx
Sep 27, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) , announces the appointment of Benjamin D. Solomon , M.D. as Managing Director of GeneDx, effective as of October 3, 2016 . GeneDx, part of OPKO's BioReference Laboratories subsidiary, specializes in genetic testing for rare hereditary
OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 19, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET) . About OPKO Health OPKO Health, Inc. is a diversified healthcare company that seeks to
OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories
Sep 13, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood , Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories , effective October 1, 2016 . Ms. Wood is a nationally respected healthcare attorney who has
OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
Sep 06, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55 th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016 . Twenty four month phase 2 efficacy, safety, pharmacokinetic, and
OPKO Health to Participate in Upcoming September Conferences
Sep 01, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK) , today announced that senior management will participate in the 11 th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9 th Annual Barrington Research Fall Investment Conference taking
OPKO Health Completes Acquisition of Transition Therapeutics
Aug 31, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NASDAQ : OPK) , announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. ( NASDAQ : TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement") which was approved by Transition Therapeutics'
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
Aug 26, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK) , announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously
OPKO Health Responds to Law Firm Notice of Investigation
Aug 23, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) , is aware of a press release by Purcell Julie & Lefkowitz, LLP , a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim involving the Company's Board of Directors.
OPKO Health Reports Improved Financial and Operating Results
Aug 08, 2016
Net income was $15.5 million and $3.6 million for the three and six months ended June 30, 2016 compared to net losses of $42.8 million and $159.9 million for the comparable periods of 2015 Consolidated revenue increased to $357.1 million from $42.4 million and to $648.1 million from $72.5 million
OPKO to Announce Second Quarter Operating and Financial Results on August 8, 2016
Aug 03, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three and six months ended June 30, 2016 , after the close of the U.S. financial markets on Monday, August 8, 2016 . OPKO's senior management will provide a business update and discuss its
OPKO Health to Acquire Transition Therapeutics
Jun 30, 2016
All-stock transaction valued at approximately US$60 million , or US$1.55 per Transition Therapeutics share OPKO to gain potential first-to-market GLP-1/Glucagon dual agonist for type 2 diabetes and obesity and phase 2 drug candidate for the treatment of androgen deficiency MIAMI & TORONTO
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
Jun 21, 2016
Approval Based Upon Two Randomized, Double Blind, Placebo Controlled Trials and an Open Label Extension Study There are Approximately 9 Million Patients in the U.S. with SHPT, Stage 3 or 4 CKD and Vitamin D Insufficiency; Large Potential U.S. Market U.S.
Displaying 61 - 80 of 366